ArticleScientific reports2026
Adsorptive performance of SPE via modified POM biochar for Pb(II) and tetracycline with concurrent antimicrobial action.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficient removal of tetracycline from aqueous media using a novel Zr-MOF/CuCoScientific reports · 2026Article
- Marine Klebsiella sp. RR1-mediated AgNPs functionalized with matcha: synthesis, characterization, and evaluation of antibacterial, antioxidant, anti-inflammatory, and gene regulation of breast cancer potentials.Microbial cell factories · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study developed a novel, eco-friendly solid-phase extraction (SPE) sorbent, modified pomegranate biochar (POM), from the agricultural waste of pomegranate peel for the efficient removal of toxic lead (Pb(II)) and the tetracycline (TC) antibiotic from aqueous solutions. Synthesized POM was comprehensively characterized using (SEM, TEM, FT-IR, and XRD) and confirmed POM’s hierarchical core-shell nanostructure, enriched surface functional groups. Optimized SPE conditions using POM achieved maximum adsorption capacities of 3900 ± 71 (RSD = 1.8%, n = 3) µmol/g for Pb(II) at (pH 7, 20 s microwave-assisted) and 87.6% ± 0.18 (RSD = 0.001%, n = 3) removal for TC at (pH 4, 30 min shaking). while PO achieved (2000 ± 71 (RSD = 2.8%, n = 3) µmol/g Pb(II); and 45.9% ± 1.8 (RSD = 0.03%, n = 3) TC removal). Although the pseudo-second-order (PSO) model accurately describes the kinetic data for Pb(II) adsorption on POM and PO, this alone does not prove a chemisorption mechanism. In general, the thermodynamic parameters, especially ΔH°, have proved that the primary mechanism is physisorption; nevertheless, the excellent fit to the PSO model suggests that the adsorption process may incorporate certain characteristics of chemisorption or that the rate-limiting step involves the sharing or exchange of electrons. While TC obeys the pseudo-first order model, indicating a physisorption mechanism for both POM and PO. Additionally, the Langmuir model provides the best fit for both POM and PO with Pb(II) and TC, indicating the formation of a monolayer on the adsorbent surface. Efficient desorption used 1 M HCl for Pb(II) (98.7% recovery) and acidified methanol (1:1 v/v HCl: methanol) for TC (99.3% recovery). The Limit of Detection (LOD) and limit of quantification (LOQ) for TC were 1.725 ppm and 5.227 ppm, while Pb(II) ions were 16.27 ppm and 50.06 ppm, respectively. The thermodynamic parameters for the adsorption of Pb(II) and TC onto both POM and PO confirm a spontaneous and endothermic process driven by an increase in entropy. POM also exhibited antibacterial activity comparable to that of a standard antibiotic, particularly against Gram-negative bacteria (E. coli and P. aeruginosa).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.